| FORTE BIOSCIENCES INC. |
| USA |
| Gesundheit |
| US34962G2084 / A40MGA |
| 37T (Frankfurt) / FBRX (NASDAQ) |
| FRA:37T, ETR:37T, 37T:GR, NASDAQ:FBRX |
| - |
| https://www.fortebiorx.co.. |
|
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases. Its primary product candidate is FB102, a proprietary anti-CD122 monoclonal antibody designed to add..
>Volltext.. |
| 277.6 Mio. EUR |
| 196.67 Mio. EUR |
| - |
| -46.25 Mio. EUR |
| -44.82 Mio. EUR |
| -3.85 EUR |
| - |
| 80.93 Mio. EUR |
| -38.49 Mio. EUR |
| 7.19 |
| - |
| -51.31% |
| - |
| - |
| - |
| - |
| FORTE BIOSCIENCES, FORTE BIO, FORTE BIOSCIENCE |
| 05.04.26 |
|